In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium.
about
Targeted delivery of therapeutics to endothelium.Innovations in studying in vivo cell behavior and pharmacology in complex tissues--microvascular endothelial cells in the spotlight.Cell-specific targeting of lipid-based carriers for ODN and DNA.Liposomes in the treatment of inflammatory disorders.Challenges in design and characterization of ligand-targeted drug delivery systems.Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.Targeted siRNA delivery to diseased microvascular endothelial cells: cellular and molecular concepts.Designing micro- and nano-particles for treating rheumatoid arthritis.Advancing musculoskeletal research with nanoscience.Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies.Nanocarriers for vascular delivery of anti-inflammatory agentsTargeted endothelial nanomedicine for common acute pathological conditions.Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent.Light and electron microscopic detection of inflammation-targeting liposomes encapsulating high-density colloidal gold in arthritic mice.Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro.Amphiphilic Scorpion-like Macromolecules as Micellar NanocarriersAnti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells.
P2860
Q30475849-6F422934-9AAA-4E48-A68F-36D9CD514F41Q35000486-08D4433B-7FBB-4559-9971-5FFCAB922231Q36272601-CF33E6D0-662A-4F18-A46C-CCE6B8216CCDQ36316769-F7E2557C-ADA3-447D-8E6B-BBA88F346F56Q36346851-942B8B7C-43EC-4DC5-8DC6-2C283572F521Q37638947-15969009-3DCA-4F20-A960-70D33E7A45D5Q37902117-C4CB3149-E8F1-4429-B7D6-4D29DCD85AA7Q37964579-4CDA6C2A-569C-4922-BA66-BE62142DDD6AQ38123687-A1CADF52-AEFC-4E4F-81FF-34EE7A79ED22Q38151092-5AB8A3E4-F92D-4E49-A0E0-1F2A0F1CBD03Q38176037-AB218E4F-C276-4FFB-8523-B02B9D70645FQ38598987-C94BE246-5585-4F3D-9F3D-E843AE0F0339Q38637805-9786A619-1E6D-4059-ACF1-50483E800DA0Q39196364-D7FF58C9-63B3-4567-946C-A7CFBF2194E8Q43664324-01B31F54-0465-4946-928E-E814A86B6219Q46562009-4011CBE1-0C97-4A87-9296-B7EE0F58B9BDQ53492650-6445FBC1-4149-4810-9E27-144BB7D6CCD1Q55392210-A523CC4C-B694-42F7-A9EF-838D67CD9E01
P2860
In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
In vitro cellular handling and ...... ivery to inflamed endothelium.
@ast
In vitro cellular handling and ...... ivery to inflamed endothelium.
@en
type
label
In vitro cellular handling and ...... ivery to inflamed endothelium.
@ast
In vitro cellular handling and ...... ivery to inflamed endothelium.
@en
prefLabel
In vitro cellular handling and ...... ivery to inflamed endothelium.
@ast
In vitro cellular handling and ...... ivery to inflamed endothelium.
@en
P2093
P50
P356
P1476
In vitro cellular handling and ...... ivery to inflamed endothelium.
@en
P2093
Dirk K F Meijer
Gerben A Koning
Gert Storm
Robbert J Kok
Sigridur A Asgeirsdóttir
P356
10.1023/A:1022298725165
P577
2003-01-01T00:00:00Z